A team of researchers from institutions in Italy and the U.S., in conjunction with several corporate entities, has found that adding a protein to lentiviral vectors can protect them from an immune ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results